EUVIMEDEUVIMED entdecken
Crossref

Updated cost-effectiveness analysis of first-line novel therapies in locally advanced or metastatic urothelial carcinoma across the UK, US, and China

Jingwen Lin, Wu Fu, Caicong You, Xiaobin Song, Maobai Liu, Hongfu Cai

World Journal of Urology · 31.10.2025 · 43 (1)

DOI: 10.1007/s00345-025-06006-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Urology, online erschienen am 31.10.2025. Verfasst von Jingwen Lin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, Fujian, China. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Carcinoma, Transitional Cell, Antineoplastic Combined Chemotherapy Protocols, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Recent clinical trials (CheckMate 901 and EV-302) have shown that nivolumab plus gemcitabine-cisplatin (N + GC) and enfortumab vedotin plus pembrolizumab (EV + P) significantly improve survival in locally advanced or metastatic urothelial carcinoma (la/mUC). Updated follow-up results from the EV-302 study were presented at the ASCO GU 2025 conference, but the economic feasibility of these therapies remains unclear. This study aims to access the cost-effectiveness of N + GC and EV + P compared to chemotherapy in la/mUC across the US, UK, and China using updated follow-up data from clinical trials. METHODS: This study employed a Markov model included three health states to evaluate health outcomes and costs. Each model cycle spanned 3 weeks with 2 years, 5 years, 10 years. Patients were divided into two subgroups according to cisplatin eligibility. The outcomes were the costs, Quality Adjusted Life Years (QALYs), and Incremental cost-effectiveness ratios (ICERs). RESULTS: For cisplatin-ineligible patients, the 10-year ICERs for EV + P were £136,919/QALY in the UK, $751,897/QALY in the US, and ¥1,158,228/QALY in China. For cisplatin-eligible patients, the 10-year ICERs were £125,441/QALY in the UK, $784,553/QALY in the US, and ¥1,096,445/QALY in China. N + GC demonstrated better cost-effectiveness, with 10-year ICERs of £71,202/QALY in the UK, $183,062/QALY in the US, and ¥259,844/QALY in China. Substantial price reductions were required for both therapies to meet willingness-to-pay thresholds. CONCLUSIONS: While EV + P offered significant survival benefits for la/mUC patients as the first-line therapy, its current pricing makes it economically unfeasible in most settings. N + GC was more cost-effective for cisplatin-eligible patients. Policymakers should consider innovative pricing strategies to ensure equitable access to treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost-Benefit AnalysisCarcinoma, Transitional CellAntineoplastic Combined Chemotherapy ProtocolsUrinary Bladder NeoplasmsUrologic NeoplasmsHumansUnited KingdomChinaUnited StatesCisplatinDeoxycytidineAntibodies, Monoclonal, HumanizedNeoplasm MetastasisGemcitabineQuality-Adjusted Life YearsMarkov ChainsCost-Effectiveness Analysis

Stichwörter der Autor:innen

Cisplatin eligibilityCost-effectivenessDrug pricingHealth policyUrothelial carcinoma

Substanzen

CisplatinDeoxycytidineAntibodies, Monoclonal, HumanizedGemcitabine

Autor:innen und Institutionen

  • Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, Fujian, China.
  • The School of Pharmacy, Fujian Medical University, Fuzhou, Fujian, China.
  • Department of Quality Management, Ganzhou Fifth People' s Hospital, Ganzhou, Jiangxi, China.
  • Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, Fujian, China. liumaobai@126.com.
  • Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, Fujian, China. caihongfu31@126.com.

Zitieren

APA

Lin, J., Fu, W., You, C., Song, X., Liu, M., & Cai, H. (2025). Updated cost-effectiveness analysis of first-line novel therapies in locally advanced or metastatic urothelial carcinoma across the UK, US, and China. World Journal of Urology, 43(1). https://doi.org/10.1007/s00345-025-06006-4

Vancouver

Lin J, Fu W, You C, Song X, Liu M, Cai H. Updated cost-effectiveness analysis of first-line novel therapies in locally advanced or metastatic urothelial carcinoma across the UK, US, and China. World Journal of Urology. 2025;43(1). doi:10.1007/s00345-025-06006-4

BibTeX
@article{Lin2025,
  author = {Lin, Jingwen and Fu, Wu and You, Caicong and Song, Xiaobin and Liu, Maobai and Cai, Hongfu},
  title = {Updated cost-effectiveness analysis of first-line novel therapies in locally advanced or metastatic urothelial carcinoma across the UK, US, and China},
  journal = {World Journal of Urology},
  year = {2025},
  volume = {43},
  number = {1},
  doi = {10.1007/s00345-025-06006-4}
}
Kostenlos starten →